No Detail Found!

A Predictive Model for Identifying the Most Effective Anti- CCR5 Monoclonal Antibody

Author(s)
Tatiana Hillman Department of Health Sciences, University of Walden,Minneapolis, Minnesota,United States
Abstract
CCR5 (R5) inhibition is increasingly being studied for its potential to prevent, treat, and cure illnesses. R5 is a transmembrane protein that interacts with the CD4 receptor and CXCR4 (X4) of T cells, allowing the attachment of HIV viruses to lymphocytes. Consequently, because R5 inhibition has performed well as a medicinal drug, such as maraviroc, many researchers have speculated that R5 inhibition via binding antibodies may effectively treat HIV patients. However, currently, there is a lack of information about the structural interaction between monoclonal antibodies (mAbs) and R5. The understanding of the structural CCR5 blockade via mAbs is limited. As a consequence, in this study, a predictive model with a sample size of N=160 was performed using non-linear regressions, in which the predicted reaction rates of the target R5 to gp120 interaction based on Michaelis-Menten enzyme kinetics of the inhibitor types (no, inhibitor (Control), competitive (CI), non-competitive (NI), and uncompetitive (UI)) were analyzed for their level to reduce the Vmax and Km of the R5-to-gp120 interaction.At a significant p-value of P<0.05, this study predicted that a non-competitive anti-R5 mAb would be the most effective inhibitor isotype since NI lowered the R5E Vmax to 20 µM/min with only a gp120S Km of 5 nM. A non-competitive anti-R5 mAb may more effectively inhibit the activity of CCR5, which may inform the production of more anti-R5 mAbs that are allosteric inhibitors of CCR5.
Publication Details
Page(s) 40-49
Published Journal: Archives of Pharmacy Practice, Volume: 14, Issue: 1, Year: 2023

Request the full text from PASTIC

Keywords
Monoclonal antibodies, Co-receptors, CCR5, Glycoproteins
0

Citations

0

Downloads

172

Views